Press Releases

 
Press Releases
  Date Title and Summary View
Sep 22, 2016
CRANBURY, N.J., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable S...
PDF
Sep 13, 2016
CRANBURY, N.J., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on Septe...
PDF
Sep 1, 2016
CRANBURY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in Ne...
PDF
Aug 31, 2016
CRANBURY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that 7 posters highlighting its Fabry program will be included in the Society for the Study of Inborn Errors of Metabolism's 2016 SSIEM Annual Symposium to be held Septem...
PDF
Aug 10, 2016
CRANBURY, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were ...
PDF
Aug 9, 2016
Significant Progress with EU Galafold Launch and Regulatory Submissions Enrollment in Pompe Phase 1/2 Clinical Study on Track with Initial Data Expected in 2H16 Elevation of "Time to Wound Closure" as Co-Primary Endpoint in Ongoing Phase 3 Study of SD-101 for Epidermolysis Bullosa $130 Million in Equity and Debt Proceeds Since March...
PDF
Aug 3, 2016
Pre-Submission Meeting Completed with Pharmaceuticals and Medical Devices Agency (PMDA) in Japan PMDA Confirms That No Further Clinical Studies Are Needed for Submission CRANBURY, N.J., Aug. 03, 2016 (GLOBE NEWSWIRE) --  Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, plans to submit...
PDF
Aug 1, 2016
CRANBURY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2016. T...
PDF
Jul 12, 2016
Former Deputy Director of FDA Division of Gastroenterology and Inborn Errors Products Brings Significant Drug Development and Pharmaceutical Industry Experience CRANBURY, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has appointed...
PDF
Jul 6, 2016
CRANBURY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare and devastating genetic neurological disease for which the...
PDF
Page:
1
... NextLast